keyword
https://read.qxmd.com/read/38709509/behavioral-interventions-to-improve-breast-cancer-screening-outreach-two-randomized-clinical-trials
#1
JOURNAL ARTICLE
Shivan J Mehta, Corinne Rhodes, Kristin A Linn, Catherine Reitz, Caitlin McDonald, Evelyn Okorie, Keyirah Williams, David Resnick, Annamaria Arostegui, Timothy McAuliffe, Colin Wollack, Christopher K Snider, MaryAnne K Peifer, Susan P Weinstein
IMPORTANCE: Despite public health efforts, breast cancer screening rates remain below national goals. OBJECTIVE: To evaluate whether bulk ordering, text messaging, and clinician endorsement increase breast cancer screening rates. DESIGN, SETTING, AND PARTICIPANTS: Two concurrent, pragmatic, randomized clinical trials, each with a 2-by-2 factorial design, were conducted between October 25, 2021, and April 25, 2022, in 2 primary care regions of an academic health system...
May 6, 2024: JAMA Internal Medicine
https://read.qxmd.com/read/38709220/phase-ii-study-to-determine-the-anti-tumor-activity-and-safety-of-simlukafusp-alfa-fap-il2v-combined-with-atezolizumab-in-esophageal-cancer
#2
JOURNAL ARTICLE
Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R Lindsay, Iwona Lugowska, James C Yang, Federico Longo, Maria de Miguel, Mariano Ponz-Sarvise, Myung-Ju Ahn, Mahmut Gumus, Stephane Champiat, Antoine Italiano, Sebastien Salas, Ruth Perets, Cagatay Arslan, Byoung C Cho, Stefan Evers, Christophe Boetsch, Daniel Marbach, David Dejardin, Nassim Sleiman, Caroline Ardeshir, Muriel Richard, Jehad Charo, Anton Kraxner, Nino Keshelava, Volker Teichgräber, Victor Moreno
PURPOSE: Reported here are results from the esophageal squamous cell carcinoma (SCC) cohort of a Phase II, non-comparative, basket study, evaluating the anti-tumor activity and safety of FAP-IL2v plus atezolizumab in patients with advanced/metastatic solid tumors (NCT03386721). EXPERIMENTAL DESIGN: Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-1; measurable metastatic, persistent, or recurrent esophageal SCC; progression on ≥1 prior therapy; and were checkpoint inhibitor naive...
May 6, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38704840/efficacy-of-intravesical-nadofaragene-firadenovec-for-patients-with-bcg-unresponsive-non-muscle-invasive-bladder-cancer-5-year-follow-up-from-a-phase-3-trial
#3
JOURNAL ARTICLE
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, Neal D Shore, Leonard G Gomella, Ashish M Kamat, Trinity J Bivalacqua, Jeffrey S Montgomery, Seth P Lerner, Joseph E Busby, Michael Poch, Paul L Crispen, Gary D Steinberg, Anne K Schuckman, Tracy M Downs, Joseph Mashni, Brian R Lane, Gennady Bratslavsky, Lawrence I Karsh, Michael E Woods, Gordon Brown, Daniel Canter, Adam Luchey, Yair Lotan, Brant A Inman, Michael B Williams, Michael S Cookson, Sam S Chang, Alexander I Sankin, Michael A O'Donnell, David Sawutz, Richard Philipson, Nigel R Parker, Seppo Yla-Herttuala, Dorte Rehm, Jørn S Jakobsen, Kristian Juul, Colin P N Dinney
BACKGROUND: Nadofaragene firadenovec-vncg is a non-replicating adenoviral vector-based gene therapy for BCG-unresponsive carcinoma in situ (CIS) with/without HG Ta/T1). We report outcomes following 5 years of planned follow-up. METHODS: This open-label phase 3 trial (NCT02773849) enrolled patients with BCG-unresponsive NMIBC in 2 cohorts: CIS ± Ta/T1 (CIS; n = 107) and Ta/T1 without CIS (Ta/T1 cohort; n = 50). Patients received 75 mL (3 × 1011 vp/mL) of Nadofaragene firadenovec intravesically once every 3 months with cystoscopy and cytology assessments, with continued treatment offered to those remaining high-grade recurrence free (HGRF)...
May 5, 2024: Journal of Urology
https://read.qxmd.com/read/38701695/aggregation-of-melanoma-tumour-site-within-western-australian-families
#4
JOURNAL ARTICLE
Sarah V Ward, Esther N Drill, Colin B Begg
BACKGROUND: Evidence is emerging that melanoma has distinct aetiologic pathways and subtypes, characterized by factors like anatomic site of the tumour. To explore genetic influences on anatomic subtypes, we examined the extent to which melanomas in first-degree relatives shared the same body site of occurrence. METHODS: Population-level linked data was used to identify the study population of over 1.5 million individuals born in Western Australia between 1945 and 2014, and their first-degree relatives...
May 2, 2024: Cancer Epidemiology
https://read.qxmd.com/read/38693429/a-critical-assessment-of-using-chatgpt-for-extracting-structured-data-from-clinical-notes
#5
JOURNAL ARTICLE
Jingwei Huang, Donghan M Yang, Ruichen Rong, Kuroush Nezafati, Colin Treager, Zhikai Chi, Shidan Wang, Xian Cheng, Yujia Guo, Laura J Klesse, Guanghua Xiao, Eric D Peterson, Xiaowei Zhan, Yang Xie
Existing natural language processing (NLP) methods to convert free-text clinical notes into structured data often require problem-specific annotations and model training. This study aims to evaluate ChatGPT's capacity to extract information from free-text medical notes efficiently and comprehensively. We developed a large language model (LLM)-based workflow, utilizing systems engineering methodology and spiral "prompt engineering" process, leveraging OpenAI's API for batch querying ChatGPT. We evaluated the effectiveness of this method using a dataset of more than 1000 lung cancer pathology reports and a dataset of 191 pediatric osteosarcoma pathology reports, comparing the ChatGPT-3...
May 1, 2024: NPJ Digital Medicine
https://read.qxmd.com/read/38686586/identifying-somatic-fingerprints-of-cancers-defined-by-germline-and-environmental-risk-factors
#6
JOURNAL ARTICLE
Saptarshi Chakraborty, Zoe Guan, Caroline E Kostrzewa, Ronglai Shen, Colin B Begg
Numerous studies over the past generation have identified germline variants that increase specific cancer risks. Simultaneously, a revolution in sequencing technology has permitted high-throughput annotations of somatic genomes characterizing individual tumors. However, examining the relationship between germline variants and somatic alteration patterns is hugely challenged by the large numbers of variants in a typical tumor, the rarity of most individual variants, and the heterogeneity of tumor somatic fingerprints...
April 30, 2024: Genetic Epidemiology
https://read.qxmd.com/read/38682463/topical-hidden-genome-discovering-latent-cancer-mutational-topics-using-a-bayesian-multilevel-context-learning-approach
#7
JOURNAL ARTICLE
Saptarshi Chakraborty, Zoe Guan, Colin B Begg, Ronglai Shen
Inferring the cancer-type specificities of ultra-rare, genome-wide somatic mutations is an open problem. Traditional statistical methods cannot handle such data due to their ultra-high dimensionality and extreme data sparsity. To harness information in rare mutations, we have recently proposed a formal multilevel multilogistic "hidden genome" model. Through its hierarchical layers, the model condenses information in ultra-rare mutations through meta-features embodying mutation contexts to characterize cancer types...
March 27, 2024: Biometrics
https://read.qxmd.com/read/38679845/prognostic-value-of-hemogram-parameters-in-osteosarcoma-the-french-os2006-experience
#8
JOURNAL ARTICLE
Paul Bastard, Nathalie Cozic, Régis Brion, Nathalie Gaspar, Sophie Piperno-Neumann, Camille Cordero, Estelle Leculée-Thébaud, Anne Gomez-Mascard, Françoise Rédini, Antonin Marchais, Raina Ikonomova, Morgane Cleirec, Valérie Laurence, Charlotte Rigaud, Rachid Abbas, Franck Verrecchia, Laurence Brugières, Véronique Minard-Colin
BACKGROUND: Previous studies have shown that neutrophil-to-lymphocyte (NLR) ratio at diagnosis and early lymphocytes recovery on doxorubicin-based chemotherapy, may impact the outcome in patients with osteosarcoma (OST). This study aimed to evaluate the prognostic value of hemogram parameters in patients with OST treated with high-dose methotrexate and etoposide/ifosfamide (M-EI) chemotherapy. MATERIALS AND METHODS: We retrospectively analyzed the prognostic value of various hemogram parameters at diagnosis and during therapy in a large consecutive cohort of patients with OST included in the French OS2006 trial and treated with M-EI chemotherapy...
April 28, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38676926/loss-of-lpar6-and-cab39l-dysregulates-the-basal-to-luminal-urothelial-differentiation-program-contributing-to-bladder-carcinogenesis
#9
JOURNAL ARTICLE
Sangkyou Lee, Jolanta Bondaruk, Yishan Wang, Huiqin Chen, June Goo Lee, Tadeusz Majewski, Rachel D Mullen, David Cogdell, Jiansong Chen, Ziqiao Wang, Hui Yao, Pawel Kus, Joon Jeong, Ilkyun Lee, Woonyoung Choi, Neema Navai, Charles Guo, Colin Dinney, Keith Baggerly, Cathy Mendelsohn, David McConkey, Richard R Behringer, Marek Kimmel, Peng Wei, Bogdan Czerniak
We describe a strategy that combines histologic and molecular mapping that permits interrogation of the chronology of changes associated with cancer development on a whole-organ scale. Using this approach, we present the sequence of alterations around RB1 in the development of bladder cancer. We show that RB1 is not involved in initial expansion of the preneoplastic clone. Instead, we found a set of contiguous genes that we term "forerunner" genes whose silencing is associated with the development of plaque-like field effects initiating carcinogenesis...
April 25, 2024: Cell Reports
https://read.qxmd.com/read/38673886/the-suppression-of-the-epithelial-to-mesenchymal-transition-in-prostate-cancer-through-the-targeting-of-myo6-using-mir-145-5p
#10
JOURNAL ARTICLE
Lee Armstrong, Colin E Willoughby, Declan J McKenna
Aberrant expression of miR-145-5p has been observed in prostate cancer where is has been suggested to play a tumor suppressor role. In other cancers, miR-145-5p acts as an inhibitor of epithelial-to-mesenchymal transition (EMT), a key molecular process for tumor progression. However, the interaction between miR-145-5p and EMT remains to be elucidated in prostate cancer. In this paper the link between miR-145-5p and EMT in prostate cancer was investigated using a combination of in silico and in vitro analyses...
April 12, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38673711/impact-of-the-covid-19-pandemic-on-head-and-neck-cancer-management-the-experience-of-the-maxillo-facial-surgery-department-of-a-french-regional-referral-center-in-a-high-incidence-area
#11
JOURNAL ARTICLE
Emilien Colin, Agnès Paasche, Alban Destrez, Bernard Devauchelle, Jérémie Bettoni, Julien Bouquet, Stéphanie Dakpé, Sylvie Testelin
Background: Cancer patients are at a high risk of complications in cases of infection, and head and neck cancers (HNC) are no exception. Since late 2019, SARS-CoV-2 has caused a global health crisis, with high rates and severe forms of the disease in cancer patients. Hospitalization, surgery and radiotherapy were rapidly described as increasing the risk of infection. Since March 2020, the Amiens University Hospital (France) has been taking care of COVID-19 patients while its maxillofacial surgery department managed HNC patients without interruption, even during lockdown periods...
April 22, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38672585/measurable-minimal-residual-disease-in-myelodysplastic-neoplasms-mds-current-state-and-perspectives
#12
REVIEW
Linsheng Zhang, George Deeb, Kristin K Deeb, Colin Vale, Deniz Peker Barclift, Nikolaos Papadantonakis
Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, and molecular and flow cytometry techniques have been used in several studies. In this review, we will highlight the evolving concept of MRD in MDS, outline the various techniques utilized, and provide an overview of the studies reporting MRD and the correlation with outcomes...
April 15, 2024: Cancers
https://read.qxmd.com/read/38668904/tubular-injury-biomarkers-to-predict-chronic-kidney-disease-and-hypertension-at-3-months-post-cisplatin-in-children
#13
JOURNAL ARTICLE
Ryan S Huang, Kelly R McMahon, Stella Wang, Hayton Chui, Asaf Lebel, Jasmine Lee, Vedran Cockovski, Shahrad Rod Rassekh, Kirk R Schultz, Tom D Blydt-Hansen, Geoffrey D E Cuvelier, Cherry Mammen, Maury Pinsk, Bruce C Carleton, Ross T Tsuyuki, Colin J D Ross, Ana Palijan, Michael Zappitelli
BACKGROUND: Urine kidney injury biomarkers measured during cisplatin therapy may identify patients at risk for adverse subsequent kidney outcomes. We examined relationships between tubular injury biomarkers collected early (early visit [EV]: first or second cisplatin cycle) and late (late visit [LV]: last or second-last cisplatin cycle) during cisplatin therapy, with 3-month post-cisplatin chronic kidney disease (CKD) and hypertension. METHODS: We analyzed data from the Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment Nephrotoxicity Study: twelve-center prospective cohort study of 159 children receiving cisplatin...
April 26, 2024: Kidney360
https://read.qxmd.com/read/38666588/cancer-an-increasing-public-health-challenge-in-the-asia-pacific
#14
EDITORIAL
Colin Binns, Wah Yun Low
No abstract text is available yet for this article.
April 26, 2024: Asia-Pacific Journal of Public Health
https://read.qxmd.com/read/38662984/genomic-correlates-of-prostate-specific-membrane-antigen-expression-and-response-to-177-lu-psma-617-a-retrospective-multicenter-cohort-study
#15
MULTICENTER STUDY
Ruben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi, Laura Graham, Roman Gulati, Colin C Pritchard, Michael C Haffner, Todd Yezefski, Jessica E Hawley, Heather H Cheng, Evan Y Yu, Petros Grivas, Robert B Montgomery, Peter S Nelson, Delphine L Chen, Thomas Hope, Amir Iravani, Michael T Schweizer
PURPOSE: While 177 Lu-PSMA-617 (LuPSMA) is an effective therapy for many patients with metastatic castration-resistant prostate cancer (mCRPC), biomarkers associated with outcomes are not well defined. We hypothesized that prostate cancer mutational profile may associate with clinical activity of LuPSMA. We devised a study to evaluate associations between mCRPC mutational profile with LuPSMA clinical outcomes. METHODS: This was a multicenter retrospective analysis of patients with mCRPC with next-generation sequencing (NGS) who received LuPSMA...
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38659962/inferring-bladder-cancer-evolution-from-mucosal-field-effects-by-whole-organ-spatial-mutational-proteomic-and-metabolomic-mapping
#16
Bogdan Czerniak, Sangkyou Lee, Sung Yun Jung, Pawel Kus, Jolanta Bondaruk, June Lee, Roman Jaksik, Nagireddy Putluri, Khanh Dinh, David Cogdell, Huiqin Chen, Yishan Wang, Jiansong Chen, Neema Nevai, Colin Dinney, Cathy Mendelsohn, David McConkey, Richard Behringer, Charles Guo, Peng Wei, Marek Kimmel
Multi-platform mutational, proteomic, and metabolomic spatial mapping was used on the whole-organ scale to identify the molecular evolution of bladder cancer from mucosal field effects. We identified complex proteomic and metabolomic dysregulations in microscopically normal areas of bladder mucosa adjacent to dysplasia and carcinoma in situ . The mutational landscape developed in a background of complex defects of protein homeostasis which included dysregulated nucleocytoplasmic transport, splicesome, ribosome biogenesis, and peroxisome...
April 10, 2024: Research Square
https://read.qxmd.com/read/38657625/spread-out-bragg-peak-measurements-using-a-compact-quality-assurance-range-calorimeter-at-the-clatterbridge-cancer-centre
#17
JOURNAL ARTICLE
Saad Shaikh, Sonia Escribano-Rodriguez, Raffaella Radogna, Laurent Kelleter, Connor Godden, Matthew Warren, Derek Attree, Ruben Saakyan, Linda Mortimer, Peter Corlett, Alison Warry, Andrew Gosling, Colin Baker, Andrew Poynter, Andrzej Kacperek, Simon Jolly
OBJECTIVE: The superior dose conformity provided by proton therapy relative to conventional X-ray radiotherapy necessitates more rigorous Quality Assurance (QA) procedures to ensure optimal patient safety. Practically however, time-constraints prevent comprehensive measurements to be made of the proton range in water: a key parameter in ensuring accurate treatment delivery. APPROACH: A novel scintillator-based device for fast, accurate water-equivalent proton range QA measurements for ocular proton therapy is presented...
April 24, 2024: Physics in Medicine and Biology
https://read.qxmd.com/read/38657098/clonal-hematopoiesis-in-patients-with-hiv-and-cancer
#18
JOURNAL ARTICLE
Nancy Gillis, Brittney L Dickey, Christelle Colin-Leitzinger, Yi-Han Tang, Ryan M Putney, Tania E Mesa, Sean J Yoder, Gita Suneja, Adam M Spivak, Ami B Patel, Martine Extermann, Anna R Giuliano, Mingxiang Teng, Jacob Kresovich, Anders Berglund, Anna E Coghill
BACKGROUND: Cancer-related deaths for people living with HIV (PWH) are increasing due to longer life expectancies and disparately poor cancer-related outcomes. We hypothesize that advanced biological aging contributes to cancer-related morbidity and mortality for PWH and cancer. We sought to determine the impact of clonal hematopoiesis (CH) on cancer disparities in PWH. METHODS: We conducted a retrospective study to compare the prevalence and clinical outcomes of CH in PWH and people without HIV (PWoH) and cancer...
April 24, 2024: Journal of Infectious Diseases
https://read.qxmd.com/read/38649544/the-role-of-urology-and-radiology-in-prostate-biopsy-current-trends-and-future-perspectives
#19
REVIEW
Benjamin M Mac Curtain, Hugo C Temperley, John A O Kelly, James Ryan, Wanyang Qian, Niall O'Sullivan, Kieran J Breen, Colin J Mc Carthy, Ian Brennan, Niall F Davis
PURPOSE: Prostate biopsy is central to the accurate histological diagnosis of prostate cancer. In current practice, the biopsy procedure can be performed using a transrectal or transperineal route with different technologies available for targeting of lesions within the prostate. Historically, the biopsy procedure was performed solely by urologists, but with the advent of image-guided techniques, the involvement of radiologists in prostate biopsy has become more common. Herein, we discuss the pros, cons and future considerations regarding their ongoing role...
April 22, 2024: World Journal of Urology
https://read.qxmd.com/read/38648535/characteristics-of-clinicians-caring-for-transgender-men-and-nonbinary-individuals-and-guideline-concordance-of-clinicians-cervical-cancer-screening-counseling-for-cisgender-individuals-versus-transgender-men-and-nonbinary-individuals-with-a-cervix
#20
JOURNAL ARTICLE
Alex McDowell, Meghan L Rieu-Werden, Steven J Atlas, Colin D Fields, Robert H Goldstein, Gabrielle D Gundersen, Jennifer S Haas, Robin T Higashi, Sandi L Pruitt, Michelle I Silver, Jasmin A Tiro, Aruna Kamineni
Purpose: We examined characteristics of clinicians caring for transgender men and nonbinary (TMNB) individuals and guideline concordance of clinicians' cervical cancer screening recommendations. Methods: Using a survey of clinicians who performed ≥10 cervical cancer screenings in 2019, we studied characteristics of clinicians who do versus do not report caring for TMNB individuals and guideline concordance of screening recommendations for TMNB individuals with a cervix versus cisgender women. Results: In our sample ( N  = 492), 49...
April 22, 2024: LGBT Health
keyword
keyword
106750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.